Brucellosis Vaccine Challenge Project

In Progress

Summary

The Brucellosis Vaccine Project is a US $30 million Pay-for-Results prize contest that aims to incentivize animal health companies to develop a vaccine against Brucella melitensis, a strain of Brucellosis that particularly affects small ruminants (goats, sheep, etc.) and is prevalent throughout developing countries. Eligible companies can receive three milestone payments at different stages that could add up to a total of US $26 million for one entrant. The contest was launched in late 2016 and could span up to ten years.

For more detailed information about the Brucellosis Vaccine Project and to get involved, visit the official project website, managed by GALVmed.

The learning journey

The problem

The Challenge of Brucellosis

Across the developing world, smallholder farmers rely heavily on livestock as a source of vital income and are an essential source of food for these households. Often, however, herds are threatened by a highly infectious disease known as Brucellosis that causes abortions, infertility, and decreased milk production; impacting a smallholder farmer’s potential to earn, support their family, and work to get out of poverty. The disease also threatens farmers’ health because it is zoonotic meaning it can cross the species barrier. While vaccines exist, they require complex management techniques that are not appropriate for developing country environments, and the disease remains endemic across much of Africa, the Middle East, and Asia.

 

Contest design

Theory of Change

The project's theory of change is that a pay-for-results prize will incentivize commercial and academic organizations to refocus efforts on developing and making market-ready an improved brucella melitensis vaccine that is safer and more efficacious than existing vaccines. The existence of an improved vaccine ready for the market will create the conditions to increase animal productivity and improve human health through reduced incidence of brucellosis. 

Prize Structure

The contest comprises three phases, with associated requirements and prizes as per the below diagram:

 

Expected impact

The project goal is to spur the development of a vaccine that will impact rural households in developing countries by reducing the incidence of Brucella melitensis and resulting abortion, infertility and decreased milk production among small ruminants. Decreased disease incidence is also expected to improve the health of the livestock producing households because Brucella melitensis is zoonotic and causes 90% of human brucellosis. The output is the creation of a vaccine that meets the MVP and potentially Best-in-Class requirements as outlined above.

 

Actual results

20

# of Competitors

1000000

Prize funds awarded (USD)

Investment by Competitors

Learning & evaluation

What We've Learned through Implementation

This table illustrates how our learning has evolved from project design through implementation. Further details can be found in the Learning Library below.

Recent News and Learning

Alt Intro Image
Published: March 08, 2018

Notes from the Evaluator: Evaluation Update for AgResults Brucellosis Vaccine Pilot

Phase 1 of the Brucellosis Vaccine Pilot (the Appl...

Alt Intro Image
Published: January 22, 2018

Brucellosis Competition Awards Reach $1,000,000 As New Winners Are Announced

Judges have praised the quality of entries to the ...

Alt Intro Image
Published: September 28, 2017

Payments Totaling US $500,000 Awarded in Global Brucellosis Vaccine Prize Competition

Additional prizes have been awarded in a global US...

Alt Intro Image
Published: September 05, 2017

Brucellosis Outbreak in India Highlights Need for Greater Disease Control

A fresh outbreak of brucellosis in India serves as...

Evaluation Design

The evaluation uses a mixed-methods approach drawing from the framework developed to evaluate innovation challenges. The evaluation uses three primary methods—a qualitative assessment, counterfactual disease study, and cost-effectiveness simulations. The Evaluator will assess the ability of the incentive to stimulate private sector involvement and innovation and ultimately to spur the development of an improved vaccine.

Evaluation Stage

The baseline is expected to occur after all applications are received to allow appropriate sampling for the interviews, which is expected to be completed in late 2018.

Project team

GWYNNETH CLAY

Team Leader

GALVMED